Table 1.
Diseases of each group at baseline and 1 year after surgery
| TA-assisted PPV | Conventional PPV | |||
|---|---|---|---|---|
| Baseline | 1 year | baseline | 1 year | |
| N (%) | N (%) | N (%) | N (%) | |
| AMD | 7 (1.8%) | 3 (1.0%) | 3 (0.8%) | 3 (1.0%) |
| BRVO | 50 (12.8%) | 41 (13.4%) | 37 (9.7%) | 29 (9.8%) |
| CRVO | 11 (2.8%) | 9 (3.0%) | 7 (1.8%) | 6 (2.0%) |
| DME | 67 (17.1%) | 60 (19.7%) | 42 (11.0%) | 34 (11.5%) |
| ERM | 24 (6.1%) | 19 (6.2%) | 41 (10.7%) | 37 (12.5%) |
| Lens luxation | 16 (4.1%) | 11 (3.6%) | 16 (4.2%) | 12 (4.1%) |
| Macroaneurysm | 10 (2.6%) | 8 (2.6%) | 9 (2.3%) | 4 (1.4%) |
| PDR | 113 (28.9%) | 85 (27.9%) | 131 (34.2%) | 101 (34.2%) |
| RRD | 80 (20.5%) | 59 (19.3%) | 77 (20.1%) | 54 (18.3%) |
| VH | 6 (1.5%) | 6 (2.0%) | 14 (3.7%) | 11 (3.7%) |
| Others | 7 (1.8%) | 4 (1.3%) | 6 (1.6%) | 4 (1.4%) |
| total | 383 (100%) | 305 (100%) | 391 (100%) | 295 (100%) |
TA; triamcinolone acetonide: PPV; pars plana vitrectomy: AMD; age-related macular degeneration: BRVO;branch retinal vein occlusion: CRVO: central retinal vein occlusion: DME; diabetic macular edema: ERM; epiretinal membrane: PDR; proliferative diabetic retinopathy: RRD; rhegmatogenous retinal detachment: VH; vitreous hemorrhage.